Charles River Laboratories and Pioneering Medicines have entered a multi-programme agreement that gives Pioneering Medicines access to artificial intelligence (AI) model Logica.
Through the agreement, Pioneering Medicines will apply Logica across a portfolio of targets with the aim of creating optimised small molecules that will lead to novel therapies for unmet medical needs.
“We are excited to work with the team at Pioneering Medicines to help accelerate the drug discovery process and deliver novel candidates to patients faster,” said Julie Frearson, Senior Vice President and Chief Scientific Officer, Charles River.
“We’re entering this collaboration with both Charles River and Valo with a shared desire to increase efficiency in drug discovery,” said Paul Biondi, President, Pioneering Medicines and Executive Partner, Flagship Pioneering. “By utilising Logica…we’re hopeful that we can more quickly advance well-characterised molecules through the development process and create and deliver novel medicines for patients sooner.”
Logica uses predictive models, chemical design and synthesis capabilities, DNA-encoded libraries and in silico high throughput screening from Valo’s Opal Computational Platform, combined with Charles River’s knowledge of high throughput screening, medicinal chemistry, ADME, biology, pharmacology, safety testing and IND submission.
